Amgen has launched Phase 3 studies (MARITIME-1 and MARITIME-2) for its lead obesity candidate, MariTide, with a revised dosing schedule following reports of high discontinuation and vomiting rates in Phase 2 trials14.
The new dosing plan involves a three-step escalation:
starting at 21 mg, increasing to 35 mg, and then 70 mg over eight weeks to improve tolerability and reduce adverse gastrointestinal events such as nausea and vomiting14.
MariTide is a peptide-antibody conjugate that activates the GLP-1 receptor while blocking the GIP receptor, aiming to provide monthly or potentially less frequent injections for obesity and related conditions2.
Endocrinologists appreciated MariTide's lack of weight loss plateau at 52 weeks and its potential for an extended dosing schedule, which could differentiate it from other treatments3.
Amgen expects Phase 3 trial results in 2027 and plans to explore the therapy in additional indications such as type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and obstructive sleep apnea12.
Sources:
1. https://www.fiercebiotech.com/biotech/amgen-adjusts-phase-3-dosing-plan-lead-obesity-candidate-maritide-after-high
2. https://www.amgen.com/stories/2025/06/inside-amgens-phase-3-maritime-program---advancing-the-future-of-obesity-care
3. https://firstwordpharma.com/story/5975441
4. https://investors.amgen.com/static-files/45992e09-afec-4735-81e6-f228739b55f0